Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure g...Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure gradient(HVPG)measurement,the minimally invasive gold standard for the diagnosis of CSPH,is not broadly available,decision rules based on non-invasive tests(NITs)are needed(2).展开更多
基金supported by the Clinical Research Group MOTION,Medical University of Vienna,Vienna,Austria-a project funded by the Clinical Research Groups Programme of the Ludwig Boltzmann Gesellschaft(grant No.LBG_KFG_22_32)with funds from the Fonds ZukunftÖsterreich(to G.S.,M.J.,and M.M.).
文摘Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure gradient(HVPG)measurement,the minimally invasive gold standard for the diagnosis of CSPH,is not broadly available,decision rules based on non-invasive tests(NITs)are needed(2).
